Minimal residual disease in breast cancer: in blood veritas.

A blood based molecular test might direct recommendations for systemic therapies in early stage breast cancer patients receiving surgery with curative intent. A new study suggests that droplet digital polymerase chain reaction can be used to detect cancer-specific DNA alterations in plasma with sensitivity suitable for monitoring minimal residual disease